Cancer Patients Who Experienced Diagnostic Genetic Testing for Cancer Susceptibility
Reactions and Behavior after the Disclosure of a Positive Test Result1
- Valérie Bonadona,
- Pierre Saltel,
- Françoise Desseigne,
- Hervé Mignotte,
- Jean-Christophe Saurin,
- Qing Wang,
- Olga Sinilnikova,
- Sophie Giraud,
- Gilles Freyer,
- Henri Plauchu,
- Alain Puisieux and
- Christine Lasset2
- Unit of Prevention and Genetic Epidemiology [V. B., C. L.] and Departments of Psycho-Oncology [P. S], Medical Oncology [F. D.], Surgical Oncology [H. M.], and Molecular Oncology [Q. W., A. P.], Comprehensive Cancer Center Léon Bérard; Department of Gastroenterology [J-C. S.] and Laboratory of Genetics [O. S., S. G.], Edouard Herriot Hospital, 69; International Agency for Research on Cancer [O. S.]; Department of Radiotherapy and Oncology, Lyon-Sud Hospital Center [G. F.]; and Department of Medical Genetics, Hôtel Dieu Hospital [H. P.], 69 008 Lyon, France
Abstract
The aim of this prospective study was to evaluate the consequences of the disclosure of a positive genetic test result to patients affected with cancer. Personal repercussions and patients’ behavior with the transmission of their results to relatives were considered. We conducted semistructured interviews with 23 cancer patients identified as carriers of a cancer-predisposing mutation for hereditary breast ovarian or nonpolyposis colorectal cancers, 1 month after the disclosure of the test result. Eight patients spontaneously expressed distressed reactions (“you no longer feel cured”), and 14 patients reported at least one negative feeling (dissatisfied, discouraged, unhappy, or worried), despite expecting to be a carrier. Sixteen patients expressed concerns about the risk of developing another cancer, and 18 were concerned for their children’s future, in that they may carry the mutation and develop a cancer. Although 8 patients found that disadvantages of knowing their genetic status outweighed the advantages, all but 1 did not regret having undergone genetic testing. All of the patients transmitted their results to at least one close relative. Although 6 of them expressed difficulties in being the only person who could transmit the information and 9 said it was a heavy responsibility, all except 1 did not want someone else to have to inform their families. Our results illustrate the potential negative impact of diagnostic genetic testing in patients with cancer. This includes distressed reactions and difficulties in transmitting their results to relatives. Future large-scale studies are warranted to confirm our findings.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵1 Supported by grants from the “Program Hospitalier de Recherche Clinique” (1997, France) and from the “Ligue Nationale contre le cancer–Comité Départemental de l’Ain” (France).
-
↵2 To whom requests for reprints should be addressed, at Unit of Prevention and Genetic Epidemiology, Comprehensive Cancer Center Léon Bérard, 28 rue Laënnec 69008 Lyon, France. E-mail: lasset{at}lyon.fnclcc.fr
-
↵3 The abbreviations used are: HBOC, hereditary breast and ovarian cancer syndrome; MMR,; HNPCC, hereditary nonpolyposis colorectal cancer syndrome; HADS, Hospital Anxiety and Depression Scale; MMR, mismatch repair.
-
- Accepted November 1, 1901.
- Received February 23, 1901.
- Revision received October 26, 1901.










